Upcoming event: 37C Health Meeting Stavanger
Regenics AS attends the 37C "Digitalization in Health" meeting on June 19-20 of June 2018 at Forus Stavanger. CEO Henrik Lund, co-chairs the meeting    
Innovation Norway grants Innovation Contract to Regenics AS
Regenics AS was May 18th 2018 awarded an Innovation Contract from Innovation Norway. The Innovation Contract has a total budget of 14.3 million NOK to support the development of Vernex®...
Regenics joins consortium for biological drug development receiving 16 mill SEK from Vinnova
Regenics Norway joins international consortium funded by 16 mill SEK from Vinnova, Sweden
Product agreement with Farmona
Regenics has today agreed with Farmona (PL) a test production of various formulations of its biomarine cosmetic ingredient LEX.  
Sapelo Skin Care US collaboration
Sapelo Skin Care's new Salmon roe Spring Tide Serum is reported by the Hollywood Reporter as one of the new Luxe Skin Care Products, in company with diamond dust, 24-karat gold,...
3D printing Agreement with Chalmers, Sweden
Regenics AS, Norway enter into an agreement with Chalmers, Sweden  on exploring Vernex™ for 3D bioprinting.
Publication: TGA Sciences, Inc., US provides collagen data for salmon roe extract
Regenics releases salmon roe collagen boosting data in human fibroblasts performed by TGA Sciences, Inc., US.  
Regenics signs CE marking consultancy agreement with Haflan Resources AS
Regenics AS signs on EU medical device consultancy agreement with Haflan Resources AS.
Innovation Norway grants loan to Regenics
Regenics is granted Innovation Norway loan of 2.5 mill NOK.
Medibiome AB collaboration
Medibiome AB, Sweden and Regenics AS Oslo agrees collaboration on evaluation of Vernex™ in human skin explant model.
Regenics AS signs with Lilleborg
Regenics AS signs LEX® delivery agreement with Lilleborg AS, Norway.

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.